Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward
Deal Struck With UK On Coronavirus Vaccine
Executive Summary
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
You may also be interested in...
Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.